<DOC>
	<DOCNO>NCT00819221</DOCNO>
	<brief_summary>The study open label , multicenter , dose find study . Depending tolerate dose 7 dose level explore study , approximately 33 patient ( 21-54 depend number cohort ) may enrol study . Three patient initially dose cohort . The primary objective study determine recommend dose ( RD ) twice daily oral dos AZD2281 either intermittent therapy 7 day 28-day schedule give continuously , administer combination liposomal doxorubicin patient advance solid tumor .</brief_summary>
	<brief_title>AZD2281 Combination With Liposomal Doxorubicin Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically cytologically confirm metastatic cancer , amenable surgery radiation therapy curative intent Measurable evaluable disease ECOG Performance status 0 2 Estimated life expectancy least 12 week More 3 prior line chemotherapy advance disease Less 28 day active treatment ( ie , treatment use treat disease ) high dose radiotherapy ( patient may continue concomitant use stable dose bisphosphonates use least 28 day prior commence study treatment pat Prior treatment &gt; 300mg/m2 cumulative dose doxorubicin equivalent Resistance anthracyclines define progressive disease anthracycline treatment within 6 month last anthracycline administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>advanced tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>dose escalation</keyword>
	<keyword>combination</keyword>
	<keyword>AZD2281</keyword>
	<keyword>liposomal doxorubicin</keyword>
	<keyword>pharmacology</keyword>
	<keyword>phase I</keyword>
	<keyword>multicenter</keyword>
</DOC>